Neoadjuvant chemotherapy in patients with advanced endometrial cancer

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer

“…There are limited data describing the relationship between NACT and survival in patients with advanced-stage endometrial cancer. [19][20][21][22][23][24] In a multicenter, retrospective review 19 of 426 patients with stage IVB endometrial cancer, 125 (29%) underwent primary chemotherapy, and 59 of those women subsequently underwent surgery. Median overall survival was 21 months in women who underwent primary surgery vs 12 months in those treated with NACT.…”

Advanced Undifferentiated Endometrial Carcinoma with No Evidence of Disease after Neoadjuvant Chemotherapy: A Case Report

“…Other studies suggest that the combination of NACT and IDS should be considered regardless of histologic subtype [6]. Patients that have undergone NACT followed by IDS have had a high rate of optimal cytoreduction and as a result, improved OS [7]. Although upfront NACT rarely diminished advanced endometrial cancer completely, the combination of NACT and IDS had positive impact on both PFS and OS [6].…”

“…Although upfront NACT rarely diminished advanced endometrial cancer completely, the combination of NACT and IDS had positive impact on both PFS and OS [6]. Nevertheless, a recent study showed that less than half of endometrial cancer patients who received NACT underwent IDS [7].…”

“…There are only a few reports of complete response to NACT in endometrial cancer. A study of 39 patients with endometrial cancer (10% of which were sarcomas) from 2002-2016 showed only 56% partial response and no complete response to NACT [7]. Two prior cases of advanced serous endometrial carcinoma were described as having no residual tumor after NACT [8].…”

Lokálisan és lokoregionálisan előrehaladott, magas kockázatú endometriumtumorok műtét előtti szisztémás előkezelése

“…Eredményeik szerint annál a betegcsoportnál, amelynél az előkezelés után kivitelezhető volt a műtét, a teljes túlélés 10 hónapos előnnyel járt. A megműtött páciensek esetén ez 16 hónap volt, az inoperábilis betegek esetében pedig 6 hónap [30]. A neoadjuváns kezelést mint választási lehetőséget lokálisan és lokoregionálisan előrehaladott endometri-umtumorok esetén a 2018-as FIGO Cancer Report is megemlíti [31].…”